BG Medicine, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported total revenue of $1,149,000 against $1,072,000 a year ago. Loss from operations was $1,661,000 against $2,605,000 a year ago. Net loss was $1,935,000 or $0.06 basic and diluted per share against $2,899,000 or $0.14 basic and diluted per share a year ago.

For the year, the company reported total revenue of $4,073,000 against $2,815,000 a year ago. Loss from operations was $14,374,000 against $22,728,000 a year ago. Net loss was $15,849,000 or $0.58 basic and diluted per share against $23,769,000 or $1.18 basic and diluted per share a year ago. Net cash outflows from operating activities were $15,288,000 against $21,333,000 a year ago. The $1.8 million increase in revenues or 45% year-over-year results principally from growth in sales from its large specialty cardiovascular laboratory provider and from third-party clinical research organizations.

For the year 2014, the company expects to increase revenues.